70804-01-2

Usage

InChI:InChI=1/C11H21ClN2O/c1-10(2)5-8(13-9(15)7-12)6-11(3,4)14-10/h8,14H,5-7H2,1-4H3,(H,13,15)

Upstream product

• 36768-62-4 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 36775-23-2 4-[(2-chloroacetyl)amino]-2,2,6,6-tetramethylpiperdine-1-oxyl 

Relevant academic research and scientific papers

Iodide-free ionic liquid with dual redox couples for dye-sensitized solar cells with high open-circuit voltage

A novel ionic-liquid mediator, 1-butyl-3-{2-oxo-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]ethyl}-1H-imidazol-3-ium selenocyanate (ITSeCN), has been successfully synthesized for dye-sensitized solar cells (DSSCs). ITSeCN possesses dual redox channels, imidazolium-functionalized 2,2,6,6-tetramethylpiperidine N-oxyl (TEMPO) and selenocyanate, which can serve as the cationic redox mediator and the anionic redox mediator, respectively. Therefore, ITSeCN has a favorable redox nature, which results in a more positive standard potential, larger diffusivity, and better kinetic heterogeneous rate constant than those of iodide. The DSSC with the ITSeCN electrolyte shows an efficiency of 8.38 % with a high open-current voltage (VOC) of 854.3 mV, and this VOC value is about 150 mV higher than that for the iodide-based DSSC. Moreover, different electrocatalytic materials were employed to trigger the redox reaction of ITSeCN. The ITSeCN-based DSSC with the CoSe counter electrode achieved the best performance of 9.01 %, which suggested that transition-metal compound-type materials would be suitable for our newly synthesized ITSeCN mediator.

Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.

We have synthesized N2-[4-(2,2,6,6-tetramethyl-1-piperidinyloxy)]actinomycin D And the related 1,2-diaminoethane and 1,3-diaminopropane derivatives and evaluated their biological properties. Binding studies with the spin-labeled actinomycin D analogues and DNA were carried out by using circular dichroism, electron spin resonance, and thermal denaturation. These studies have suggested that the derivatives bind to DNA and that their DNA-binding modes are similar but not identical. Spin-labeled actinomycin D derivatives were less potent in inhibiting Escherichia coli DNA-dependent RNA polymerase reaction than actinomycin D and were less toxic to L1210 cells in vitro than the parent compound. Spin-labeled actinomycin D derivatives were more common than the parent compounds against P-388 leukemia cells in vitro with little or no toxicity.

Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics

Small molecule choline kinase inhibitors having the following formula: are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting choline kinase enzymatic activity, and methods of treating tumors by administering an effective amount of a Formula I compound.